These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32755597)

  • 1. Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma.
    Golkowski M; Lau HT; Chan M; Kenerson H; Vidadala VN; Shoemaker A; Maly DJ; Yeung RS; Gujral TS; Ong SE
    Cell Syst; 2020 Aug; 11(2):196-207.e7. PubMed ID: 32755597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via MEK1/ERK/ELK1 signaling in hepatocellular carcinoma.
    Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
    Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
    Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
    Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZnAs@SiO
    Huang Y; Zhou B; Luo H; Mao J; Huang Y; Zhang K; Mei C; Yan Y; Jin H; Gao J; Su Z; Pang P; Li D; Shan H
    Theranostics; 2019; 9(15):4391-4408. PubMed ID: 31285768
    [No Abstract]   [Full Text] [Related]  

  • 7. ARK5 promotes doxorubicin resistance in hepatocellular carcinoma via epithelial-mesenchymal transition.
    Xu T; Zhang J; Chen W; Pan S; Zhi X; Wen L; Zhou Y; Chen BW; Qiu J; Zhang Y; Yang Q; Feng X; Bai X; Liang T
    Cancer Lett; 2016 Jul; 377(2):140-8. PubMed ID: 27126361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
    Huang XY; Ke AW; Shi GM; Zhang X; Zhang C; Shi YH; Wang XY; Ding ZB; Xiao YS; Yan J; Qiu SJ; Fan J; Zhou J
    Hepatology; 2013 Jun; 57(6):2235-47. PubMed ID: 23316005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
    Xia H; Ooi LL; Hui KM
    Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretory Clusterin: A Promising Target for Chemoresistance of Hepatocellular Carcinoma.
    Zhang J; Wu M; Xu Y; Song Q; Zheng W
    Mini Rev Med Chem; 2020; 20(12):1153-1165. PubMed ID: 32228422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of CD29-ILK-Akt signaling-mediated epithelial-mesenchymal transition of liver epithelial cells and chemoresistance and radioresistance in hepatocellular carcinoma cells.
    Jiang X; Wang J; Zhang K; Tang S; Ren C; Chen Y
    Med Oncol; 2015 May; 32(5):141. PubMed ID: 25805567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implication of Frizzled 2 expression and its association with epithelial-to-mesenchymal transition in hepatocellular carcinoma.
    Asano T; Yamada S; Fuchs BC; Takami H; Hayashi M; Sugimoto H; Fujii T; Tanabe KK; Kodera Y
    Int J Oncol; 2017 May; 50(5):1647-1654. PubMed ID: 28350091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frizzled 2-induced epithelial-mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma.
    Ou H; Chen Z; Xiang L; Fang Y; Xu Y; Liu Q; Hu Z; Li X; Huang Y; Yang D
    Cancer Sci; 2019 Apr; 110(4):1169-1182. PubMed ID: 30677195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma.
    Mehdizadeh A; Somi MH; Darabi M; Jabbarpour-Bonyadi M
    Mol Biol Rep; 2016 Feb; 43(2):107-16. PubMed ID: 26767647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROR1 Expression and Its Functional Significance in Hepatocellular Carcinoma Cells.
    Cetin M; Odabas G; Douglas LR; Duriez PJ; Balcik-Ercin P; Yalim-Camci I; Sayan AE; Yagci T
    Cells; 2019 Mar; 8(3):. PubMed ID: 30832318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
    Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
    Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
    Yu M; Han G; Qi B; Wu X
    Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.